Biolegend, 108127, Brilliant Violet 421™ anti-mouse Ly-6A/E (Sca-1) Antibody
125microl
Catalog Number: 108127
Loading…
| Verified Reactivity | Mouse |
|---|---|
| Antibody Type | Monoclonal |
| Host Species | Rat |
| Immunogen | IL-2-dependent mouse T-cell line (CTL-L) |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA). |
| Preparation | The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. |
| Concentration | µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.) |
| Storage & Handling | The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. |
| Application | FC - Quality tested |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Recommended Usage |
|---|
| Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. |
| Excitation Laser | Violet Laser (405 nm) |
|---|
| Application Notes | The D7 antibody has been reported to induce T cell activation and inhibit TCR-induced IL-2 production. Additional reported applications (for the relevant formats) include: Western blotting1,2, immunoprecipitation1, in vitro lymphocyte activation3-6, induction of redirected lysis7, induction of T cell inhibitory signalling8, immunofluorescence9, and immunohistochemical staining of acetone-fixed frozen sections13 and Bouin-fixed, paraffin-embedded samples9. The two Sca-1 recognizing clones D7 and E13-161.7 have been shown to bind distinct epitopes due to the inability of D7 to block the binding of E13-161.7.14 |
|---|
| Application References(PubMed link indicates BioLegend citation) | Ortega G, et al. 1986. J. Immunol. 137:3240. (WB, IP) Palfree RGE, et al. 1986. Immunogenetics 23:197. (WB) Codias EK, et al. 1990. J. Immunol. 144:2197. Malek TR, et al. 1986. J. Exp. Med. 164:709. Codias EK, et al. 1990. J. Immunol. 145:1407. Ivanov V, et al. 1994. J. Immunol. 153:2394. Karlhofer FM, et al. 1991. J. Immunol. 146:3662. Fleming T, et al. 1994. J. Immunol. 153:1955. van Bragt MPA, et al. 2005. Biol. Reprod. 73:634. (IF, IHC) Umland O, et al. 2007. J. Immunol. 178:4147. Cridland SO, et al. 2009. Blood Cell. Mol. Dis. 45:149. (FC) PubMed Pronk CJ, et al. 2011. J. Exp Med. PubMed English A, et al. 2000. J. Immunol. 165:3763. (IHC) Bamezai A and Rock KL. 1995. Proc. Natl. Acad. Sci. USA 92:4294. Wiesner DL, et al. 2015. PLoS Pathog. 11:1004701. PubMed |
|---|
| Product Citations | Ho YH, et al. 2019. Cell Stem Cell. 25:407. PubMed Liu C, et al. 2023. STAR Protoc. 4:102123. PubMed Siatra P, et al. 2023. NPJ Regen Med. 8:13. PubMed Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed Kfoury YS, et al. 2021. Cell Stem Cell. 28:2090. PubMed Dave A, et al. 2023. Front Genet. 13:894597. PubMed Sohn J, et al. 2022. Blood Adv. 6:2557. PubMed Jaiswal AK, et al. 2020. Immunobiology. 225:151956. PubMed Baryawno N et al. 2019. Cell. 177(7):1915-1932 . PubMed Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed Groenen AG, et al. 2022. J Lipid Res. 63:100167. PubMed Chen J, et al. 2021. Sci Adv. 7:. PubMed Pessoa Rodrigues C, et al. 2021. Sci Adv. 7:. PubMed Forte D, et al. 2020. Cell Metab. 32:829. PubMed Sykes DB et al. 2016. Cell. 167(1):171-186 . PubMed Al-Rifai R, et al. 2022. Nat Commun. 13:6592. PubMed Mitchell K, et al. 2018. J Exp Med. 215:1709. PubMed Goldsmith JR, et al. 2020. Nat Commun. 11:2591. PubMed Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed Kotfis K, et al. 2020. British Journal of Pharmacology. 49(1):66-72. PubMed Jia W, et al. 2021. Nat Commun. 12:2118. PubMed Park D, et al. 2020. Cancer Res. 80:4172. PubMed Mansell E, et al. 2020. Cell Stem Cell. . PubMed Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed La Rose AM, et al. 2021. Mol Metab. 53:101265. PubMed Yuzugullu H, et al. 2015. Nat Commun. 6: 8501. PubMed Runyan CE, et al. 2020. Aging Cell. 19:00. PubMed LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed Thongthip S, et al. 2016. Genes Dev. 30: 645 - 659. PubMed Zhou T, et al. 2022. Sci Adv. 8:eabj9617. PubMed Nijnik A, et al. 2012. Blood. 119:1522. PubMed Koide S, et al. 2022. iScience. 25:103603. PubMed Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed Chavez JS, et al. 2022. Cells. 11:. PubMed Evavold CL, et al. 2021. Cell. 184(17):4495-4511.e19. PubMed Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed Severe N et al. 2019. Cell Stem Cell. 25(4):570-583 . PubMed Dingler FA, et al. 2020. Mol Cell. . PubMed Pessoa Rodrigues C, et al. 2020. Sci Adv. 6:eaaz4815. PubMed Reyna DE et al. 2017. Cancer cell. 32(4):490-505 . PubMed Cui Y, et al. 2020. Eur J Pharmacol. 881:173233. PubMed |
|---|
| RRID | AB_10898327 (BioLegend Cat. No. 108127) AB_2563064 (BioLegend Cat. No. 108128) |
|---|
| Structure | Ly-6 multigene family, 18 kD |
|---|
| Distribution | Hematopoietic stem cells, activated T cells and B cells, subset of resting B cells and T cells |
|---|
| Function | Regulates B and T cell responses |
|---|
| Cell Type | B cells, Hematopoietic stem and progenitors, Mesenchymal Stem Cells, T cells |
|---|
| Biology Area | Immunology, Stem Cells |
|---|
| Antigen References | 1. Rock KL, et al. 1989. Immunol. Rev. 111:195. 2. Morrison SJ, et al. 1994. Immunity 1:661. 3. Spangrude GJ, et al. 1988. J. Immunol. 141:3697. 4. Malek T, et al. 1986. J. Exp. Med. 164:709. |
|---|
| Gene ID | 110454 |
|---|
| UniProt | View information about Ly-6A/E on UniProt.org |
|---|
| Clone | D7 |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | Sca-1 |
|---|
| Isotype | Rat IgG2a, κ |
|---|
